Skip to content
Article Rich – Lifestyle
Author:
Adlai Nortye Ltd.
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
August 17, 2026
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
August 3, 2026
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
July 16, 2026
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
July 13, 2026
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
April 16, 2026